Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients

Antiviral Therapy

Volumn 16, Issue 3, 2011, Pages 395-404

  Schapiro, Jonathan M ^a   Boucher, Charles A B ^b,c   Kuritzkes, Daniel R ^d   Van De Vijver, David A ^b   Llibre, Josep M ^e   Lewis, Marilyn ^f   Simpson, Paul ^f   Delogne, Christophe ^f   McFadyen, Lynn ^f   Chapman, Douglass ^g   Perros, Manos ^f   Valdez, Hernan ^g   Van Der Ryst, Elna ^f   Westby, Mike ^f  

^a National Hemophilia Center   (Israel)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OPTIMIZED BACKGROUND THERAPY SUSCEPTIBILITY SCORE; OUTCOME ASSESSMENT; PHENOTYPE; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; VIRAL TROPISM; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RECEPTORS, CCR5; RNA, VIRAL; T-LYMPHOCYTES; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD;

EID: 79959470960     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1759     Document Type: Article

References (27)

1. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857): a potent, orally bioavailable and selective small-molecule inhibitor of the chemokine receptor CCR5 with broadspectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732. (Pubitemid 41552605)
2. + T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010; 54:394-397.
3. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
4. Fätkenheuer G, Nelson M, Lazzarin A, et al. for the MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455.
5. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. (Pubitemid 46541620)
6. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
7. Baxter JD, Schapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006; 80:10794-10801. (Pubitemid 44628925)
8. De Luca A, Weidler J, Di Giambenedetto S, et al. Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. J Acquir Immune Defic Syndr 2007; 45:411-417. (Pubitemid 47057667)
9. Swanstrom R, Bosch RJ, Katzenstein D, et al. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1- infected subjects. J Infect Dis 2004; 190:886-893. (Pubitemid 39120964)
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. (Updated 10 January 2011. Accessed 11 March 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
11. Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 2007; 21:179-185. (Pubitemid 46036925)
12. Coakley E, Chappey C, Flandre P, et al. Defining lower (L) and upper (U) phenotypic clinical cutoffs (CCO) for tipranavir (TPV), lopinavir (LPV), saquinavir (SQV) and amprenavir (APV) co-administered with ritonavir (r) within the RESIST dataset using the PhenoSense assay (Monogram [MGRM] Biosciences). Antivir Ther 2006; 11 Suppl 1:S81.
13. ANRS-AC11: Resistance Group. Genotype interpretation: nucleoside and nucleotide reverse transcriptase inhibitors. (Updated July 2008. Accessed 11 March 2011.) Available from www.hivfrenchresistance.org/2008/Algo-2008.pdf
14. HIV French Resistance: HIV-1 genotypic drug resistance interpretation's algorithms. (Updated 2002. Accessed 11 March 2011.) Available from www.hivfrenchresistance.org/2002/tab2.html
15. DHHS/FDA/CDER guidance for industry. Antiretroviral drugs using plasma RNA measurements - clinical considerations for accelerated and traditional approval. (Updated October 2002. Accessed 11 March 2011.) Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070968.pdf
16. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons, Inc. 1989; pp. 140-145.
17. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16:62-68.
18. Hardy WD, Gulick R, Mayer H, et al. Efficacy and safety of maraviroc in treatment-experienced patients infected with R5 HIV-1: 96-week combined analysis of the MOTIVATE 1 and 2 studies. 9th International Congress on Drug Therapy in HIV Infection. 9-13 November 2008, Glasgow, UK. Abstract O425.
19. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404-412. (Pubitemid 41669173)
20. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577. (Pubitemid 33096808)
21. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-458.
22. Liu L, May S, Richman DD, et al. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS 2008; 22:835-839. (Pubitemid 351563832)
23. Saag M, Goodrich J, Fätkenheuer G, et al. A double-blind, placebo controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199:1638-1647.
24. Anderson JA, Jiang H, Ding X, et al. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses 2008; 24:685-694. (Pubitemid 351748774)
25. Castor D, Vlahov D, Hoover DR, et al. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART. J Med Virol 2009; 81:1323-1335.
26. Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 2005; 191:1325-1330.
27. Zaccarelli M, Lorenzini P, Checcherini-Silberstein F, et al. Historical resistance profile helps to predict salvage failure. Antivir Ther 2009; 14:285-291.